• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Oblong Appoints Two New Directors to its Board

    5/30/23 8:00:00 AM ET
    $OBLG
    $PMCB
    $PTPI
    $SNPX
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OBLG alert in real time by email

    Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors

    Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board.

    "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transformation and corporate finance and will be a tremendous addition to our team. In addition, we want to acknowledge and thank Jim and Matt and for their many excellent contributions to Oblong as they retire from service to the Company."

    Jonathan Schechter currently serves as a partner of The Special Equities Group, a division of Dawson James Securities, Inc., a full-service investment bank specializing in healthcare, biotechnology, technology, and clean-tech sectors, since April 2021. Mr. Schechter is one of the founding partners of The Special Equities Opportunity Fund, a long-only fund that makes direct investments in micro-cap companies and has served in this capacity since August 2019. He currently serves on the board of directors of Synaptogenix, Inc., a clinical-stage biopharmaceutical company (NASDAQ:SNPX), and previously served as a director of DropCar, Inc. Mr. Schechter also serves as a member of the Board of Directors of PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company developing pharmaceutical products. He has extensive experience analyzing and evaluating the financial statements of public companies. Mr. Schechter earned his A.B. in Public Policy/Political Science from Duke University and his J.D. from Fordham University School of Law.

    Robert Weinstein is currently the Chief Financial Officer of Synaptogenix, Inc., a publicly traded biotechnology company pursuing pharmaceutical treatments for neurological diseases (NASDAQ:SNPX) following its spin-off from Neurotrope, Inc. where he was Chief Financial Officer since October 2013. In addition, Mr. Weinstein performs work as a consultant for Petros Pharmaceuticals, Inc., (NASDAQ:PTPI) which is the surviving company from the merger of Metuchen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on men's health, and Neurotrope, Inc. He has extensive accounting and finance experience, spanning almost 40 years, as a public accountant, investment banker, healthcare private equity fund principal and chief financial officer. From September 2011 to the present, Mr. Weinstein has also been an independent accounting and finance consultant for several healthcare companies in the pharmaceutical and biotechnology industries. Mr. Weinstein also serves as a member of the Board of Directors of Xwell, Inc. (Formerly XpresSpa Group, Inc.) (NASDAQ:XWEL), a health and wellness company whose core asset, XpresSpa, is a leading airport retailer of spa services, related health and wellness products and bio-surveillance on behalf of the US Center for Disease Control (CDC), and PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company developing pharmaceutical products. Mr. Weinstein received an MBA degree in finance and international business from the University of Chicago Graduate School of Business, is a Certified Public Accountant (inactive), and received his BS degree in accounting from the State University of New York at Albany.

    Forward looking and cautionary statements

    This press release and any oral statements made regarding the subject of this release contain forward-looking statements as defined under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, that address activities that the Company assumes, plans, expects, believes, intends, projects, estimates or anticipates (and other similar expressions) will, should or may occur in the future are forward-looking statements. The Company's actual results may differ materially from its expectations, estimates and projections, and consequently you should not rely on these forward-looking statements as predictions of future events. Without limiting the generality of the foregoing, forward-looking statements contained in this press release include statements regarding the expected contribution from two newly appointed Board members. The forward-looking statements are based on management's current belief, based on currently available information, as to the outcome and timing of future events, and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. A list and description of these and other risk factors can be found in the Company's Annual Report on Form 10-K for the year ending December 31, 2022, the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2023 and in other filings made by the Company with the SEC from time to time. Any of these factors could cause the Company's actual results and plans to differ materially from those in the forward-looking statements. Therefore, the Company can give no assurance that its future results will be as estimated. The Company does not intend to, and disclaims any obligation to, correct, update or revise any information contained herein.

    About Oblong, Inc.

    Oblong (NASDAQ:OBLG) provides innovative and patented technologies that change the way people work, create, and communicate. Oblong's flagship product Mezzanine™ is a meeting technology platform that offers simultaneous content sharing to optimize audience engagement and situational awareness. For more information, visit www.oblong.com and Oblong's Twitter and Facebook pages.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230530005070/en/

    Get the next $OBLG alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OBLG
    $PMCB
    $PTPI
    $SNPX

    CompanyDatePrice TargetRatingAnalyst
    Oblong Inc.
    $OBLG
    12/31/2021$13.00 → $5.00Buy
    Dawson James
    PharmaCyte Biotech Inc.
    $PMCB
    11/8/2021Neutral
    HC Wainwright & Co.
    Oblong Inc.
    $OBLG
    8/5/2021$15.00Buy
    Dawson James
    More analyst ratings

    $OBLG
    $PMCB
    $PTPI
    $SNPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oblong Bolsters Decentralized AI Strategy with Bittensor ($TAO) Purchase and Staking

      $1.65M deployed into $TAO from new capital raised in June 2025 5,025 tokens acquired and fully staked into the Bittensor ecosystem Oblong, Inc. (NASDAQ:OBLG, "Oblong" or the "Company")), today announced it has strengthened its decentralized AI treasury strategy by acquiring 5,025 $TAO tokens for $1.65 million, using proceeds from its recent $7.5 million financing. This follows the Company's June 6, 2025, announcement to pivot toward decentralized AI, with the purchase of $TAO at an average price of $328.38 per token reinforcing its commitment to innovative, high-growth assets for investors. The $TAO investment underscores Oblong's focus on Bittensor's decentralized AI protocol, which

      7/1/25 9:20:00 AM ET
      $OBLG
      Computer Software: Programming Data Processing
      Technology
    • TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

      New name and stock symbol highlight strategic commitment to TAO, the leading AI cryptocurrency NEW YORK, July 1, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), formerly Synaptogenix, Inc. (NASDAQ:SNPX), announces that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TAOX," effective at the market open today, July 1, 2025. The new name and trading symbol coincides with the Company's previously announced digital asset treasury strategy focused exclusively on acquiring and staking TAO cryptocurrency. Executive Chairman Joshua Silverman commented, "With our team's deep knowledge of the TAO ecosystem and relationships in

      7/1/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xpres Spa Named One of Yelp's Most Loved Airport Brands

      NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- XWELL (NASDAQ:XWEL) ("XWELL" or the "Company"), a leading provider of wellness solutions for people on the go, is proud to share that Xpres Spa has been named one of Yelp's "Most Loved Airport Brands." Based off millions of reviews and ratings from U.S. travelers, Xpres Spa was ranked 10 out of 25 brands that have earned a loyal following among travelers. "Yelp's recognition reinforces what we've seen firsthand: travelers are increasingly seeking comfort and quality at the airport," said Ezra Ernst, CEO of XWELL. "Whether they're arriving early to browse wellness-focused products or turning to sleeping pods during a long delay, they know Xpres S

      6/27/25 8:05:43 AM ET
      $XWEL
      Other Consumer Services
      Consumer Discretionary

    $OBLG
    $PMCB
    $PTPI
    $SNPX
    SEC Filings

    See more
    • SEC Form 424B3 filed by XWELL Inc.

      424B3 - XWELL, Inc. (0001410428) (Filer)

      7/3/25 4:05:23 PM ET
      $XWEL
      Other Consumer Services
      Consumer Discretionary
    • SEC Form 8-K filed by Oblong Inc.

      8-K - Oblong, Inc. (0000746210) (Filer)

      7/2/25 7:51:30 AM ET
      $OBLG
      Computer Software: Programming Data Processing
      Technology
    • SEC Form EFFECT filed by XWELL Inc.

      EFFECT - XWELL, Inc. (0001410428) (Filer)

      7/1/25 12:15:16 AM ET
      $XWEL
      Other Consumer Services
      Consumer Discretionary

    $OBLG
    $PMCB
    $PTPI
    $SNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dawson James reiterated coverage on Oblong with a new price target

      Dawson James reiterated coverage of Oblong with a rating of Buy and set a new price target of $5.00 from $13.00 previously

      12/31/21 10:02:27 AM ET
      $OBLG
      Computer Software: Programming Data Processing
      Technology
    • HC Wainwright & Co. initiated coverage on PharmaCyte Biotech

      HC Wainwright & Co. initiated coverage of PharmaCyte Biotech with a rating of Neutral

      11/8/21 6:05:27 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dawson James initiated coverage on Oblong with a new price target

      Dawson James initiated coverage of Oblong with a rating of Buy and set a new price target of $15.00

      8/5/21 6:20:37 AM ET
      $OBLG
      Computer Software: Programming Data Processing
      Technology

    $OBLG
    $PMCB
    $PTPI
    $SNPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wizenberg Gaelle Sandra bought $1,987 worth of shares (1,201 units at $1.65), increasing direct ownership by 402% to 1,500 units (SEC Form 4)

      4 - XWELL, Inc. (0001410428) (Issuer)

      9/13/24 5:41:59 PM ET
      $XWEL
      Other Consumer Services
      Consumer Discretionary
    • Director Wizenberg Gaelle Sandra bought $551 worth of shares (299 units at $1.84) (SEC Form 4)

      4 - XWELL, Inc. (0001410428) (Issuer)

      7/22/24 8:47:43 AM ET
      $XWEL
      Other Consumer Services
      Consumer Discretionary

    $OBLG
    $PMCB
    $PTPI
    $SNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Singer William S. was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 700% to 10,566 units (SEC Form 4)

      4 - TAO Synergies Inc. (0001571934) (Issuer)

      7/2/25 4:07:09 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Weinstein Robert was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 696% to 10,574 units (SEC Form 4)

      4 - TAO Synergies Inc. (0001571934) (Issuer)

      7/2/25 4:06:45 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Chairman Silverman Joshua was granted 41,919 shares and covered exercise/tax liability with 16,768 shares, increasing direct ownership by 1,644% to 26,681 units (SEC Form 4)

      4 - TAO Synergies Inc. (0001571934) (Issuer)

      7/2/25 4:06:21 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OBLG
    $PMCB
    $PTPI
    $SNPX
    Financials

    Live finance-specific insights

    See more
    • XWELL Reports First Quarter 2025 Results, Advancing Mission to Liberate Science-Proven Wellness

      NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- XWELL, Inc. (NASDAQ:XWEL) ("XWELL" or the "Company"), a pioneer in science-proven, accessible wellness, today reported results for the first quarter ended March 31, 2025. With a growing portfolio of in-airport and off-airport wellness brands, XWELL continues to redefine what wellness access looks like --connecting high-impact, science-backed care to everyday consumers wherever they are. From leading the nation's biosecurity response to building tech-forward wellness spaces in transportation hubs and neighborhoods alike, XWELL is extending wellness beyond the elite and into real life. Operating Highlights: Reported first quarter 2025 revenue of $

      5/20/25 4:15:18 PM ET
      $XWEL
      Other Consumer Services
      Consumer Discretionary
    • Oblong Announces Financial Results for First Quarter 2025 and Provides Business Update

      Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), today reported financial results for the three months ended March 31, 2025, and provided updates on the Company's business and strategy. "As of March 31, 2025, we're in a very strong financial position with $4.3 million in cash, zero debt, and a fresh $518,000 boost from warrant exercises in April 2025. This war chest gives us the firepower to drive our strategy into late 2026. We're aggressively pursuing high-growth M&A opportunities, zeroing in on recurring revenue models, digital currency and AI-driven innovators that can supercharge profitability and operating efficiency. In a dynamic market, our disciplined approach ensures we're

      5/13/25 8:30:00 AM ET
      $OBLG
      Computer Software: Programming Data Processing
      Technology
    • Oblong Announces Financial Results for Fourth Quarter 2024 and Provides Business Update

      Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), an innovator in collaboration solutions, today reported financial results for the fourth quarter and fiscal year ending December 31, 2024, and provided updates on the Company's business and strategy. "As of December 31, 2024, our financial footing remains strong, with $5.0 million in cash and zero debt. During Q4, we raised $231,000 from common stock warrant exercises and streamlined operations to increase efficiency, resulting in expected annual savings of $1.2 million. We believe we're on track to maintain liquidity into mid-2026. In September 2024, we proudly regained full compliance with Nasdaq's listing standards. Our focus is no

      3/18/25 4:10:00 PM ET
      $OBLG
      Computer Software: Programming Data Processing
      Technology

    $OBLG
    $PMCB
    $PTPI
    $SNPX
    Leadership Updates

    Live Leadership Updates

    See more

    $OBLG
    $PMCB
    $PTPI
    $SNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

      Strategic capital deployment into TAO advances Synaptogenix's blockchain treasury model, leveraging BitGo's custody, trading and staking capabilities to generate token-based yield NEW YORK, June 24, 2025 /PRNewswire/ -- Synaptogenix (NASDAQ:SNPX) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy focused exclusively on artificial intelligence (Al) and machine learning. BitGo, the leading infrastructure provider of digital asset solutions, has been selected to provide qualified custody, staking and trading services for Synaptogenix's TAO holdings. BitGo brings unmatched expertise and a proven track record to help Synaptogen

      6/24/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

      Singular focus on Bittensor (TAO), the leading AI token byadoption and market capitalization James Altucher to lead TAO token strategy initiatives Planned initial acquisition of $10 million in TAO equates to over two times the Company's current market capitalization; total acquisition target of $100 million NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altuch

      6/9/25 9:00:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XWELL Appoints Ezra Ernst as New President and Chief Executive Officer

      NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (NASDAQ:XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today announced the appoint of Ezra T. Ernst as Chief Executive Officer. Ernst succeeds Scott Milford, who will serve in a consultative role through the end of 2024. "Ezra brings the combination of operational and strategic excellence to the position, while also having a deep understanding of the company, the industry and key partners," said XWELL Chairman of the Board, Bruce Bernstein. "This strategic leadership change will propel XWELL forward in its next phase. I trust that Ezra will deliver purpose-driven growth for XWELL through c

      9/5/24 8:00:00 AM ET
      $XWEL
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

      SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

      11/14/24 5:17:37 PM ET
      $PTPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PharmaCyte Biotech Inc.

      SC 13G/A - PharmaCyte Biotech, Inc. (0001157075) (Subject)

      11/13/24 11:19:35 AM ET
      $PMCB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

      SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

      11/13/24 11:14:05 AM ET
      $PTPI
      Biotechnology: Pharmaceutical Preparations
      Health Care